EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Elevance Health (0HG8) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Elevance Health $351, price $387, upside -9.2%, quality 60 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · GB · Home US

EH Some data Sep 24, 2026

Elevance Health

0HG8 · LSE

Overvalued / MonitorQuality is not strong enough to offset the price risk.

!Fair value $351.28 · Overvalued (−9.2%)
✓Quality 60/100
✓Healthy Growth (revenue 5y +10.3 %/yr)
!Thin margins · 2.5% net margin (TTM)
✓Low debt · generates free cash flow
✓1.8% dividend yield · Well covered
✓Ranks above peers (6/10)
!Narrow moat 39/100
!Evidence only medium, so the estimate is less certain
!Weak on valuation: 21 out of 100
!Weak on future: 7 out of 100
Watch Elevance Health for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$541.94 $270.59 Fair Value $351.28 May 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range $270.59 – $541.94 · fair‑value band $186.64 – $476.35 · the $386.96 price screens above the $351.28 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Elevance Health in your weekly email

Every Wednesday you see whether Elevance Health is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other.

Show more

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. The company also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers. In addition, it provides healthcare related services and capabilities, including specialty care enablement and utilization management support for specialized clinical domains; behavioral health and comprehensive care management services; palliative care services and management; virtual care; and payment integrity, subrogation, clinical data exchange through its HealthOS platform, research and data, reporting and clinical analytics, information technology, and business process support services, as well as manages home health, post-acute institutional management, and durable medical equipment costs; and supports plans in managing home and community-based services. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is based in Indianapolis, Indiana.

Stock analysis

Elevance Health (0HG8) currently trades at $386.96, while our model-based Fair Value estimate is $351.28, so the stock looks roughly fairly valued today (gap 10.2%).

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of $389.97 per share, and 9 of the 24 models we run sit above the $386.96 price.

Bear case: the Asset-Based group reads lowest at $113.67, and 15 of the 24 models stay below the price. Evidence for this calculation is medium.

Scenario range: $186.64 (bear) to $476.35 (bull), the price of $386.96 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 60/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Elevance Health reported revenue of $199B in FY2025 versus $139B in FY2021, a compound +9.5%/yr. Reported net income was $5.7B in FY2025, compounding −1.9%/yr from FY2021.

Key figures

Market cap $86.9B · P/E ratio 0.2 · EPS (TTM) $25.40 · Dividend yield 1.8% · Net margin 2.8% · Return on equity 11.1% · Return on assets (EBIT) 30.9% · Operating margin 4.6%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).

What moves the price

The share trades about 9% below its 52-week high and 41% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −9% fair-value upside, at −9%, 0HG8 screens cheaper than that median.

Fair Value models

Bear $186.64 Fair Value $351.28 Bull $476.35
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($14.02 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF $152.25 $286.45 $501.12 77
Growth DCF $151.91 $277.30 $472.29 76
Residual Income $158.76 $190.51 $269.11 76
All 24 models by family
DCF Models
FCF DCF $152.25 $286.45 $501.12 77
Owner Earnings $284.43 $508.51 $866.96 74
5Y Revenue Exit $173.55 $334.68 $549.92 70
5Y EBITDA Exit $222.62 $432.55 $690.76 73
5Y P/E Exit $238.16 $463.54 $715.24 69
10Y Revenue Exit $156.43 $303.07 $519.70 64
10Y EBITDA Exit $195.24 $371.87 $631.33 66
10Y P/E Exit $205.18 $393.66 $650.73 62
Earnings-Based
Graham-Dodd $148.86 $612.61 $834.53 64
Lynch FV $154.16 $220.23 $286.29 61
PEG = 1.0 $154.16 $220.23 $286.29 57
EPV $153.87 $185.29 $212.39 74
Multiples
P/E Multiple $361.21 $481.61 $602.01 63
P/S Multiple $279.11 $372.15 $465.19 58
P/B Multiple $279.11 $372.15 $465.19 55
EV/EBIT $285.67 $395.93 $506.19 66
EV/EBITDA $290.06 $401.78 $513.51 67
EV/Revenue $190.98 $292.16 $393.34 53
Asset-Based
NCAV (Graham) $84.83 $113.67 $169.66 54
Growth DCF
Growth DCF $151.91 $277.30 $472.29 76
Rev-Margin DCF $173.55 $331.16 $527.02 71
Economic Profit
Residual Income $158.76 $190.51 $269.11 76
ROIC Compounder $153.87 $199.94 $271.83 71
Growth Earnings
Growth-Adj P/E $272.98 $389.97 $506.96 67

Open the full fair value analysis →

Notify me when 0HG8 reaches fair value

Put 0HG8 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 60/100

Of which business quality 58 · Market factors (momentum, volatility) 65

Profitability 58
Margins and returns on capital today
Quality Growth 54
Are margins and returns improving?
Cashflow 31
Earnings quality: real cash, not paper profit
Fin. Strength 47
Balance sheet, leverage, solvency risk
Investment 80
Disciplined investing over empire-building
Low Volatility 73
Calm price path (market factor)
Momentum 60
Price trend over the last 3–12 months (market factor)
52W Momentum 66
Distance to the 52-week high (market factor)
Net Issuance 100
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 77/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+12.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.3%
Start year 2020 (pandemic). Over 10 years: +9.7% a year
Revenue growth 27 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.3%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+8.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+6.4%
Dividend (yield on the price)1.8%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.6.4% vs 10.6%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.7% → 3%
Start year 2020 (pandemic)

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+21.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+1.4%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in USD, USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +19.0% a year for the price and −1.0% for the forecasts.
Forecast 2026 (sales)−1.5%
Forecast 2027 (sales)+2.2%
Projected 2028 (sales)+2.2%
Projected 2029 (sales)+2.1%
Projected 2030 (sales)+2.1%

Watch 0HG8, get fair value alerts →

Compare Elevance Health with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Healthcare Plans” was too small, so the broader sector is used.)Health Care · 2433 stocks

Beats the sector median on 6/10 measures
Overall it ranks above its sector peers.
Valuation
Quality Score 60 · Above median
Fair Value upside −9.2% · Above median
Profitability
Return on equity (TTM) 11.1% · Above median
Return on assets 3.8% · Above median
Net margin (TTM) 2.5% · Below median
Operating margin (TTM) 4.6% · Below median
Growth and dividend
Revenue growth 1.4% · Below median
Dividend yield (TTM) 1.8% · Above median
Balance sheet
Debt / equity 0.48× · Highest 25%

Valuation Multiplesvs Health Care median · lower = cheaper

P/E (TTM) 0.2× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)21 · sector 6
FUTURE (revenue growth)7 · sector 26
PAST (return on equity)45 · sector 13
HEALTH (low debt)76 · sector 96
DIVIDEND (yield)35 · sector 33

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Healthcare Plans stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
UnitedHealth Group UNH $367.08 $295.49 −20%
CVS Health Corporation CVS $85.69 $42.44 −50%
The Cigna Group CI $271.83 $495.96 +82%
Humana Inc HUM $379.68 $146.91 −61%
Molina Healthcare, Inc MOH $189.10 $219.06 +16%
Oscar Health, Inc OSCR $29.60 $59.20 +100%
Progyny, Inc PGNY $25.19 $35.44 +41%
Alignment Healthcare, Inc ALHC $8.21 $7.45 −9%
Medi Assist Healthcare Services Limited MEDIASSIST ₹298.50 ₹226.12 −24%
Healthconn Corp 6665 17.10 TWD 13.18 TWD −23%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Elevance Health · Fair Value
$351.28 −9%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Elevance Health Fair Value". https://www.fairvalue-calculator.com/stock/0HG8

Frequently asked questions

Is Elevance Health (0HG8) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $351.28 versus a price of $386.96, about −9% upside (fairly valued).
What is the fair value of 0HG8?
Our model-based fair value for Elevance Health is $351.28 (as of Sep 24, 2026), built from audited fundamentals. The current price: $386.96.
What is the quality score of 0HG8?
Elevance Health has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Elevance Health (0HG8)?
Our model-based price target is the fair value of $351.28 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario $186.64, optimistic scenario $476.35. It is a calculation from audited fundamentals, not an analyst target.
What is the Elevance Health stock forecast for 2026?
Our models put fair value at $351.28, about −9% upside versus a price of $386.96 (fairly valued). Cautious scenario $186.64, optimistic scenario $476.35. The calculation is refreshed regularly with new filings.
What is the revenue of Elevance Health (0HG8)?
Elevance Health reported trailing-twelve-month revenue of about $201B (latest available figure, as of Sep 24, 2026).
Does Elevance Health pay a dividend?
Elevance Health currently shows a dividend yield of about 1.77% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Elevance Health (0HG8)?
For today's price to be fair in a discounted-cash-flow model, Elevance Health would have to grow free cash flow by +21.8 % per year for five years (discount rate 9.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +10.3 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 0HG8 use?
Our models discount Elevance Health at 9.5 %: a base by market capitalisation (unknown), damped by beta 0.68, country premium for United Kingdom. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Elevance Health that is +21.8 % per year a year over ten years, using the same discount rate (9.5 %) and the same formula as our fair value.
How much growth has Elevance Health (0HG8) delivered so far?
Over the past 5 years revenue at Elevance Health grew +10.3 % a year. The price currently implies +21.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Elevance Health (0HG8) growing?
The median revenue growth in the sector is +7.3 % a year. That is the yardstick for the growth priced into Elevance Health (+21.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Elevance Health (0HG8)?
The free-cash-flow yield on the price is 2.76 %: that much free cash flow Elevance Health produces per unit of market value. When it exceeds the discount rate of our models (9.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Elevance Health (0HG8)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Elevance Health it is $351.28 per share (as of Sep 24, 2026), against a price of $386.96. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Elevance Health stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 0HG8 trades above its calculated fair value: price $386.96, fair value $351.28, a gap of about −9% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0HG8?
No. The price is what the market pays today ($386.96); the fair value is what the company's own numbers justify ($351.28). For Elevance Health the two are $35.68 per share apart. That gap is exactly why we show both numbers side by side.
How much is Elevance Health worth?
The market values Elevance Health at about $86.9B (market capitalisation, as of Sep 24, 2026). Per share that is $386.96; our models calculate a fair value of $351.28 per share.
What do the bullish and bearish scenarios say about 0HG8?
Our models span a range for Elevance Health: cautious scenario $186.64, base $351.28, optimistic $476.35 per share (as of Sep 24, 2026, price $386.96). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 0HG8?
Elevance Health trades at a price-to-earnings ratio of 0.2 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $351.28 is built from several models across several years.
How solid is the balance sheet of Elevance Health (0HG8)?
Balance-sheet figures for Elevance Health (as of Sep 24, 2026): return on equity 11.1%, debt of 0.48 per unit of equity. They feed the Quality Score of 60/100, which measures business quality independently of the share price.
How far is 0HG8 from its 52-week high?
Elevance Health trades at $386.96, about 9% below its 52-week high of $424.97 and 41% above the low of $274.85 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $351.28 is for.
Which stocks are comparable to Elevance Health?
From the same area (Healthcare) we also value UnitedHealth Group, CVS Health Corporation, The Cigna Group, Humana Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Elevance Health stock attractive at the current price?
The data as of Sep 24, 2026: price $386.96, calculated fair value $351.28 (−9%), Quality Score 60/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0HG8 calculated?
We run Elevance Health through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $351.28, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Elevance Health itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Elevance Health (0HG8)?
The closing price on Oct 2, 2026 was $386.96. Our model-based fair value is $351.28, about −9% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Elevance Health right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range ($186.64 to $476.35) leaves room in how you read the outcome.
Where does the earnings growth of Elevance Health (0HG8) come from?
Earnings per share at Elevance Health grew +12.0 % a year from 2014 to 2025. Broken into its drivers: revenue per share +11.8 %, EBIT margin +17.3 %, tax rate +3.9 %, residual (interest, one-offs) −17.8 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Elevance Health

How large is the market capitalisation of Elevance Health (0HG8)?
The market capitalisation of Elevance Health is $86.9B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Elevance Health (0HG8)?
Earnings per share at Elevance Health are $25.40 (price ÷ EPS = P/E 0.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Elevance Health (0HG8)?
The dividend yield of Elevance Health is 1.8% (payout 27.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Elevance Health (0HG8)?
The net margin of Elevance Health is 2.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Elevance Health (0HG8)?
The return on equity (ROE) of Elevance Health is 11.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Elevance Health (0HG8)?
On an EBIT basis the return on assets of Elevance Health is 30.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Elevance Health (0HG8)?
The operating margin of Elevance Health is 4.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Elevance Health (0HG8)?
Revenue at Elevance Health is growing +1.4% versus a year earlier (3y avg +8.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Elevance Health (0HG8)?
Earnings per share at Elevance Health are growing −13.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Elevance Health (0HG8) carry?
The net debt of Elevance Health is $23.2B (fiscal year 2025, ≈ 7.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Elevance Health in the live analysis

One click puts Elevance Health on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.